- Email: [email protected]
ARIA guidelines for allergic rhinitis in specialist practices. A randomized controlled trial with ebastine
S26 Abstracts
SATURDAY 6
ARIA Guidelines for Allergic Rhinitis in Specialist Practices. A Randomized Controlled Trial With Ebastine
J. Klossek1, F. Neukirch2, P. Gehanno3, T. Bodez4, F. Liard5, N. Janin6, J. Bousquet7; 186021, Hopital de la Milétrie - Dpt ORL, Poitiers, FRANCE, 275018, INSERM 408, Paris, FRANCE, 375018, Groupe Bichat-ClaudeBernard, Paris, FRANCE, 475019, ORL, Paris, FRANCE, 537800, MG, Saint-Epain, FRANCE, 675013, Almirall SAS, Paris, FRANCE, 734000, Faculté de Médecine, Montpellier, FRANCE. RATIONALE: Guidelines are more effective than free-treatment choice in the treatment of allergic rhinitis. The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines were validated in the treatment of intermittent and persistent allergic rhinitis induced by pollens. METHODS: A multicenter, open label, parallel, randomized study comparing two therapeutic strategies in allergic rhinitis was carried out in specialist practices. In the first strategy, 417 patients received a step treatment using ARIA guidelines with ebastine as oral anti-histamine at 10 or 20 mg/day according to severity of symptoms. In the second strategy (422 patients), investigators had a free choice of treatment. Co-primary outcome measures were quality-of-life (RQLQ) and daily symptom-medication scores. RESULTS: Of the 839 randomized patients, 94.2% returned the baselinevisit questionnaires and 88.6% returned the post-treatment period questionnaires. Overall and individual domain scores in the RQLQ were similar in the two treatment groups at baseline. During the treatment period, there were significant improvements in overall and individual domain scores in both groups. However, the improvements in overall scores in the Guidelines Group (–1.70 ± 1.20) were significantly greater than in the Free choice treatment Group (–1.52 ± 1.22, p<0.02). For all domains the improvement in RQLQ scores were greater than 0.5. CONCLUSIONS: The use of a simple therapeutic scheme based on ARIA Guidelines with ebastine offers patients a significant improvement
J ALLERGY CLIN IMMUNOL FEBRUARY 2004
SATURDAY 6
ARIA Guidelines for Allergic Rhinitis in Specialist Practices. A Randomized Controlled Trial With Ebastine
J. Klossek1, F. Neukirch2, P. Gehanno3, T. Bodez4, F. Liard5, N. Janin6, J. Bousquet7; 186021, Hopital de la Milétrie - Dpt ORL, Poitiers, FRANCE, 275018, INSERM 408, Paris, FRANCE, 375018, Groupe Bichat-ClaudeBernard, Paris, FRANCE, 475019, ORL, Paris, FRANCE, 537800, MG, Saint-Epain, FRANCE, 675013, Almirall SAS, Paris, FRANCE, 734000, Faculté de Médecine, Montpellier, FRANCE. RATIONALE: Guidelines are more effective than free-treatment choice in the treatment of allergic rhinitis. The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines were validated in the treatment of intermittent and persistent allergic rhinitis induced by pollens. METHODS: A multicenter, open label, parallel, randomized study comparing two therapeutic strategies in allergic rhinitis was carried out in specialist practices. In the first strategy, 417 patients received a step treatment using ARIA guidelines with ebastine as oral anti-histamine at 10 or 20 mg/day according to severity of symptoms. In the second strategy (422 patients), investigators had a free choice of treatment. Co-primary outcome measures were quality-of-life (RQLQ) and daily symptom-medication scores. RESULTS: Of the 839 randomized patients, 94.2% returned the baselinevisit questionnaires and 88.6% returned the post-treatment period questionnaires. Overall and individual domain scores in the RQLQ were similar in the two treatment groups at baseline. During the treatment period, there were significant improvements in overall and individual domain scores in both groups. However, the improvements in overall scores in the Guidelines Group (–1.70 ± 1.20) were significantly greater than in the Free choice treatment Group (–1.52 ± 1.22, p<0.02). For all domains the improvement in RQLQ scores were greater than 0.5. CONCLUSIONS: The use of a simple therapeutic scheme based on ARIA Guidelines with ebastine offers patients a significant improvement
J ALLERGY CLIN IMMUNOL FEBRUARY 2004